Risk factors for cardiovascular disease in women

Comment

Eddie Vos et al. JAMA. 2005.

. 2005 Dec 14;294(22):2843; author reply 2844.

doi: 10.1001/jama.294.22.2843-a.

No abstract available

Comment on

Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.
Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Ridker PM, et al. JAMA. 2005 Jul 20;294(3):326-33. doi: 10.1001/jama.294.3.326. JAMA. 2005. PMID: 16030277

Revised indications for statin therapies.
Kalmansohn RB, Kalmansohn RW, Schiff DL. Kalmansohn RB, et al. Angiology. 2001 May;52(5):367-8. doi: 10.1177/000331970105200512. Angiology. 2001. PMID: 11386390 No abstract available.
[Cardiovascular risk reduced under moderate LDL-C target values].
Laufs U. Laufs U. Dtsch Med Wochenschr. 2016 Oct;141(22):1602. doi: 10.1055/s-0042-117708. Epub 2016 Nov 4. Dtsch Med Wochenschr. 2016. PMID: 27824410 German. No abstract available.
The healthy adherer effect.
Andersohn F, Willich SN. Andersohn F, et al. Arch Intern Med. 2009 Sep 28;169(17):1635-6; author reply 1636. doi: 10.1001/archinternmed.2009.324. Arch Intern Med. 2009. PMID: 19786686 No abstract available.
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Brunzell JD, et al. J Am Coll Cardiol. 2008 Apr 15;51(15):1512-24. doi: 10.1016/j.jacc.2008.02.034. J Am Coll Cardiol. 2008. PMID: 18402913 Review. No abstract available.
Prevention of cardiovascular ischemic events: high-risk and secondary prevention.
Genest J, Pedersen TR. Genest J, et al. Circulation. 2003 Apr 22;107(15):2059-65. doi: 10.1161/01.CIR.0000067881.26274.BD. Circulation. 2003. PMID: 12707251 Review. No abstract available.